Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.

导出 LinkOut

翻译打印收藏纠错

第一作者： Hidemasa,Matsuo

第一单位： Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

作者： Hidemasa,Matsuo ^[1] ; Kenichi,Yoshida ^[2] ; Kana,Nakatani ^[3] ; Yutarou,Harata ^[1] ; Moe,Higashitani ^[1] ; Yuri,Ito ^[1] ; Yasuhiko,Kamikubo ^[1] ; Yusuke,Shiozawa ^[1] ; Yuichi,Shiraishi ^[4] ; Kenichi,Chiba ^[5] ; Hiroko,Tanaka ^[5] ; Ai,Okada ^[6] ; Yasuhito,Nannya ^[5] ; June,Takeda ^[3] ; Hiroo,Ueno ^[3] ; Nobutaka,Kiyokawa ^[3] ; Daisuke,Tomizawa ^[7] ; Takashi,Taga ^[8] ; Akio,Tawa ^[9] ; Satoru,Miyano ^[10] ; Manja,Meggendorfer ^[6] ; Claudia,Haferlach ^[11] ; Seishi,Ogawa ^[11] ; Souichi,Adachi ^[3]

作者单位： Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan. ^[1] Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan. ^[2] Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. ^[3] Department of Pediatrics, The University of Tokyo, Tokyo, Japan. ^[4] Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan. ^[5] Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ^[6] Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan. ^[7] Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan. ^[8] Department of Pediatrics, Shiga University of Medical Science, Otsu, Japan. ^[9] Higashiosaka Aramoto Heiwa Clinic, Higashiosaka, Japan. ^[10] MLL Munich Leukemia Laboratory, Munich, Germany. ^[11] Institute for the Advanced Study of Human Biology (WPI ASHBi), Kyoto University, Kyoto, Japan; and. ^[12] Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden. ^[13]

主题词成年人(Adult);儿童(Child);组蛋白赖氨酸N-甲基转移酶(Histone-Lysine N-Methyltransferase);人类(Humans);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);突变(Mutation);髓淋巴细胞性白血病蛋白质(Myeloid-Lymphoid Leukemia Protein);预后(Prognosis);原癌基因蛋白质类p21(ras)(Proto-Oncogene Proteins p21(ras))

DOI 10.1182/bloodadvances.2020002457

PMID 32991719

发布时间 2021-09-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览13

Blood advances

2020年4卷19期

4623-4631页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.

Blood advances

相似文献

Blood advances

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.

Blood advances

相似文献

Blood advances

相关期刊

检索历史清除